Results 51 to 60 of about 181,126 (162)

Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells

Journal of Pharmacological Sciences, 2018
Immune checkpoint blockade (ICB) is a promising novel therapy for multiple cancer types; however, most patients show limited or no clinical response.
Zhiqi Xie, Yukio Ago, Naoki Okada, Masashi Tachibana   +3 more
doaj   +1 more source

Deciphering the role of signal regulatory protein α in immunotherapy for solid tumors

Frontiers in Immunology
Therapies targeting immune checkpoints like programmed death receptor-1 and programmed death ligand-1 have demonstrated remarkable effectiveness in combating cancer.
Yulong Zhou, Xiyang Tang, Weiguang Du, Chen Shu, Chen Shu, Xiaolong Yan, Nan Ma, Jinbo Zhao   +7 more
doaj   +1 more source

Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1

JAAD Case Reports, 2021
Claire J. Wiggins, BS, Van K. Morris, MD, Natasha K. Klimas, MD, Priyadharsini Nagarajan, MD, PhD, Jonathan L. Curry, MD, Kristen N. Richards, MD   +5 more
doaj   +1 more source

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial

Cancer Medicine
Background The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis.
Qinglian Tang, Xinke Zhang, Xiaojun Zhu, Huaiyuan Xu, Guohui Song, Jinchang Lu, Hao Wu, Chuangzhong Deng, Fei Ai, Yingchun Zhang, Jin Wang   +10 more
doaj   +1 more source

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

Cancer Medicine, 2019
Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously ...
Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura   +20 more
doaj   +1 more source

Roles of AKR1C1 in Non-small Cell Lung Cancer

Frontiers in Bioscience-Landmark
Lung cancer is associated with high global incidence and mortality, with non–small cell lung cancer (NSCLC) comprising the majority of cases. Although targeted therapies including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase ...
Xinran Zhang, Qi Zhang, Yuting Chang, Gaohua Han   +3 more
doaj   +1 more source

Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)

Journal for ImmunoTherapy of Cancer
Peritoneal carcinomatosis is a frequent metastatic condition in gastroesophageal cancer and is associated with poor prognosis and limited therapeutic options.
Geoffrey Ku, Prasad S Adusumilli, David Restle, Kyohei Misawa, Alfredo Amador-Molina, Srijita Banerjee   +5 more
doaj   +1 more source

Clinical response of immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in advanced signet-ring-cell gastric cancer

Future Oncology
The clinical benefit of PD-1/PD-L1-based immunotherapy in gastric signet ring cell carcinoma (GSRCC) remains unclear. This study evaluated the efficacy of first-line immunotherapy in advanced GSRCC.This single-center retrospective cohort study assessed the clinical response of patients with advanced GC diagnosed from November 2019 to January 2025 after
Liang, Jie, Chen, Xinhua, Liang, Huayuan, Zhao, Liying, Yu, Jiang   +4 more
openaire   +3 more sources

Research Progress on PD-1/PD-L1 Inhibitors in Treatment of Advanced, Relapsed, and Refractory NK/T-cell Lymphoma

Zhongliu Fangzhi Yanjiu
Extranodal NK/T cell lymphoma (ENKTL) is a rare subtype of extranodal non-Hodgkin lymphoma (NHL) with strong invasiveness. Although the chemotherapy regimen based on asparaginase is the standard treatment for advanced patients, the prognosis needs to be ...
Jing YANG, Tao WU
doaj   +1 more source

Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma. [PDF]

Cureus, 2017
Nordmann N, Hubbard M, Nordmann T, Sperduto PW, Clark HB, Hunt MA.   +5 more
europepmc   +1 more source